[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"safety-issues\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:safety-issues":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,42,67,94,119,141,168,192,217,239,262,287,309,329,357,379,417,438,460,480,503,529,555,580,602],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100553365","besmart-secure-storage-counseling-in-the-inpatient-setting-100553365",false,"NCT06485141","BeSMART Secure Storage Counseling in the Inpatient Setting","BeSMART","Inclusion Criteria (must meet ALL):\n\n1. Provision of signed and dated informed consent form\n2. Caregiver of child hospitalized on a pediatric hospital medicine service aged 0-17\n3. English or Spanish speaking caregiver\n4. Access to necessary resources for participating in a technology-based intervention follow-up assessments (e-mail and telephone)\n\nExclusion Criteria:\n\n1. Caregivers of children admitted for firearm injury\n2. Caregivers of children with a firearm injury within the last 3 months\n3. Caregivers of children admitted with a primary psychiatric diagnosis including suicidal ideation, self-harm, homicidal ideation, aggression, or intentional ingestion\n4. Caregivers of children who are admitted to a surgical co-management team\n\nNon-gun owners will be excluded intermittently throughout the enrollment period based on proportion of gun owners enrolled. For every 30 study participants enrolled, 10 must be gun owners. Non-gun owner enrollment will be paused until 10 gun owners are enrolled and this cycle will repeat for every 30 participants enrolled at each study site.",true,"ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","Firearm injuries are the leading cause of death for American youth. While most of these deaths are homicides, approximately one third are suicides and 5% are unintentional shootings where a child gains access to an unsecured firearm and unintentionally pulls the trigger injuring or killing themselves or someone else. Secure firearm storage in the home has been shown to significantly reduce the risk of both unintentional shootings and intentional self-harm behavior. Additionally, approximately 75% of the guns that show up on school grounds come from the homes of youth or their family members or friends. Despite evidence that secure storage counseling delivered in the pediatric outpatient setting significantly improves secure storage behavior AND recommendations from the American Academy of Pediatrics to provide secure storage counseling during well child checks, rates of counseling continue to be low. The Be SMART program is aligned with the American Academy of Pediatrics policy statement and recommendations and provides a scalable solution to efficient counseling in the clinical setting. However, except for one single site inpatient study, the efficacy of the Be SMART program has not been formally evaluated in the inpatient pediatric setting.\n\nBy rigorously evaluating the efficacy of specific secure storage interventions like Be SMART the investigators can eventually improve counseling frequency with the goal of increasing gun safety behaviors and reducing firearm injuries and deaths in youth.\n\nThe investigators hypothesize the Be SMART educational intervention, when delivered in the pediatric inpatient setting, will lead to significant improvement in the primary gun safety behavior endpoint and the secondary endpoint among both gun owners and non-gun owners when compared to control group.",[27,28],"Firearm Injury","Safety Issues","RECRUITING","2026-05-06",{"date":32,"type":33},"2026-05-11","ACTUAL",{"date":35,"type":33},"2025-09-20",{"date":37,"type":21},"2026-12-30",{"name":39,"class":40},"Vanderbilt University Medical Center","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100597460","phase-1-safety-tolerability-pk-and-pd-of-sss55-in-healthy-subjects-100597460","NCT07058779","Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects","A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of SSS55 Injection in Healthy Subjects in China","Inclusion Criteria:\n\n1. Healthy subjects aged 18 to 45 years old (including the boundary value), regardless of gender;\n2. The subjects voluntarily participated in the clinical trial and signed the informed consent form;\n3. Men with a weight of ≥50 kg, women with a weight of ≥45 kg, and those with a body mass index (BMI) ranging from 19 to 28 kg\u002Fm2 (including the critical value);\n4. Those who underwent vital sign assessment, physical examination, blood routine, urine routine, blood biochemistry, coagulation function, pregnancy examination (for women of childbearing age), 12-lead ECG, chest X-ray\u002Flung CT during screening, and the results showed no abnormalities or the abnormalities had no clinical significance;\n5. Be willing to receive the MV-ACYW meningococcal vaccine and pneumococcal vaccine 14 days or more before randomization.\n\nExclusion Criteria:\n\n* 1\\) Those with a clear history of drug or food allergies, or a known history of hypersensitivity reactions that are clinically significant to the research intervention measures or related compounds or commonly used antibacterial agents;\n\n  2\\) Those with a history of any serious clinical diseases in the past or present, including but not limited to those in the digestive system, cardiovascular system, respiratory system, urinary system, musculoskeletal system, endocrine system, immune system, neuropsychiatric system, hematological system, etc. (except those deemed eligible for enrollment by the researcher);\n\n  3\\) First-degree relatives with a known history of meningococcal infection or a history of meningococcal infection;\n\n  4\\) Those with contraindications to meningococcal vaccination (with a history of epilepsy or other brain diseases, etc.);\n\n  5\\) There was or suspected active viral, bacterial, fungal or parasitic infection within 14 days prior to screening, including herpes, shingles or cold sores;\n\n  6\\) A history of recurrent infections of unknown cause; Or systemic antibiotics (intravenous antibiotics, oral antibiotics, etc., excluding topical application antibiotics) have been used within 90 days before administration;\n\n  7\\) There is a history of Gilbert syndrome or the researcher assesses that it meets the diagnostic criteria for the disease;\n\n  8\\) Received treatment with blood products within 6 months prior to administration;\n\n  9\\) Those who have undergone major surgical operations within 4 weeks prior to administration or have not fully recovered from any previous invasive procedures;\n\n  10\\) Suffering from syphilis (Treponema pallidum antibody positive) or AIDS (HIV antibody positive), or active hepatitis C (hepatitis C virus antibody positive), or active hepatitis B (hepatitis B surface antigen positive);\n\n  11\\) A history of malignant tumors in the past or present;\n\n  12\\) Any drugs (including prescription drugs, over-the-counter drugs, Chinese herbal medicines, etc.) or health supplements have been used within 2 weeks before administration (if determined by the investigator, the time interval from the start of administration of the drug in this trial \\> Five half-lives, and the corresponding subjects can also be enrolled.","45 Years",{"count":51,"type":21},26,[53],"PHASE1","This study was a single-dose, randomized, double-blind, placebo-controlled study of SSS55 injection to evaluate the safety, tolerability, PK characteristics, immunogenicity and preliminary efficacy characteristics of single-dose SSS55 injection in healthy individuals.",[28],"2026-02-26",{"date":58,"type":33},"2026-03-02",{"date":60,"type":33},"2025-08-04",{"date":62,"type":21},"2027-12",{"name":64,"class":65},"Shenyang Sunshine Pharmaceutical Co., LTD.","INDUSTRY",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100451881","phase-4-real-world-safety--efficacy-experience-of-empagliflozin-with-or-without-metformin-in-t2dm-patients---ease-study-100451881","NCT05164263","Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study","Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in Patients With Type II Diabetes Mellitus","EASE","Inclusion Criteria:\n\nPatient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informed consent. Patient uncontrolled on oral antidiabetics and lifestyle modification for at least 3 months. Patient who are empagliflozin naive. eGFR ˃60 mL\u002Fmin\u002F1.73m2.\n\nExclusion Criteria:\n\nType 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection, renal and\u002For hepatic dysfunctions, where RFT and Urine R\u002FE is abnormal, Diabetic Ketoacidosis and\u002For hyperosmolar hyperglycemic state, severe hypoglycemia, Pregnant or lactating women, Pancreatitis, any serious complications or hypersensitivity.","65 Years",{"count":77,"type":21},2000,[79],"PHASE4","Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.\n\nStudy design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.\n\nSample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal Infections, Nausea, Vomiting, Diarrhea, Abdominal Discomfort, Flatulence, Asthenia, Indigestion and Other side effects (if any).\n\nFollow up visits: After recruitment, patient is supposed to have three visits for follow-ups.\n\nVisit 1: 4 to 6 weeks of initiation of therapy. Visit 02: At 12 weeks of initiation of therapy. Visit 03: At 24 weeks of initiation of therapy.\n\nLABORATORY TESTING:\n\nReputable Lab is considered for laboratory testing of diabetes patients i.e. HbA1C%, FBG, RFT and urine R\u002FE. The certified clinical lab will be responsible for receiving and analyzing clinical sample. Patients will have special discount of upto 50% for study related laboratory investigations.\n\nWhere in Urine Routine Examination (Urine R\u002FE), we consider as follows:\n\n* Visual Examination:\n\n  * Urine color: Normal (Yellow), Pale Yellow, Dark Yellow, Brown, Red or Pink or any other.\n  * Urine clarity: Clear, slightly Cloudy, cloudy or turbidity\n* Chemical Examination:\n\n  * Specific gravity\n  * pH\n  * Bilirubin\n  * Urobilinogen\n  * Protein\n  * Ketone\n  * Leukocyte Esterase\n* Microscopic Examination:\n\n  * Red Blood Cells:\n  * Epithelial Cells:\n  * Amorphous:\n  * Pus Cells\n  * Bacteria\n  * Yeast\n  * Casts\n  * Crystals\n\nWhere in Renal Function Test (RFT), we consider as follows:\n\n* Blood Urea Nitrogen (BUN): mg\u002FdL\n* Serum Creatinine: mg\u002FdL\n* Estimated Glomerular Filtration Rate (eGFR): mL\u002Fmin\u002F1.73 m2",[82,83,28],"Type II Diabetes Mellitus","Efficacy, Self","2026-01-20",{"date":86,"type":33},"2026-01-22",{"date":88,"type":33},"2021-04-01",{"date":90,"type":21},"2027-08-31",{"name":92,"class":65},"Getz Pharma",6,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100450215","phase-1-phase12a-study-for-ipg7236-in-patients-with-advanced-solid-tumors-100450215","NCT05142592","Phase1\u002F2a Study for IPG7236 in Patients With Advanced Solid Tumors","A Phase 1\u002F2a, Multi-center, Non-randomized, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. A written informed consent must be signed prior to performing any study procedures.\n2. Male or females 18 years or older.\n3. Diagnosis of advanced or recurrent, histologically or cytologically confirmed, a solid malignancy that is either metastatic or unresectable.\n\n   * Part 1 Dose Escalation: all solid tumor types.\n   * Part 2 Dose Expansion: the following tumor types are tentatively planned for expansion. It may be modified based on the results from the dose escalation phase.\n\n     * Renal cancer\n     * Triple-negative breast cancer\n     * Head and neck cancer\n     * Melanoma\n4. Subjects must have failed established standard medical anti-cancer therapies for a given tumor type or have been intolerant to such therapy, or in the opinion of the Investigator have been considered ineligible for standard therapies on medical grounds.\n5. Subjects must demonstrate measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n6. Subjects must have a life expectancy of ≥ 3 months.\n7. Subjects must have an Eastern Cooperative Oncology Group(ECOG) performance status score of 0 to 1.\n8. Subjects must have adequate hematologic and organ function as indicated by the following laboratory values\n\n   1. Hematologic\n\n      * Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL.\n      * Platelet count ≥ 100×109\u002FL\n      * Hemoglobin ≥ 9 g\u002FdL (subjects that required transfusion or growth factor need to demonstrate stable hemoglobin for 7 days of 9 g\u002FdL)\n   2. Renal\n\n      • Estimated glomerular filtration rate（eGFR ）≥ 50 mL\u002Fmin OR serum creatinine ≤ 1.5 × upper limit of normal (ULN).\n   3. Hepatic\n\n      * Aspartate aminotransferase levels ≤ 3 ×ULN (if liver metastases are present, ≤ 5× ULN)\n      * Alanine aminotransferase levels ≤ 2.5 × ULN (if liver metastases are present, ≤ 5×ULN).\n      * Bilirubin ≤ 1.5 × ULN\n   4. Coagulation • Prothrombin time and activated partial thromboplastin time ≤ 1.5 × ULN\n9. Subjects must be able to swallow and retain orally administered medication.\n10. Patients must be willing and able to comply with all scheduled visits, treatment, laboratory tests, be able to take oral medication, and other requirements of the study\n11. Female patients of child-bearing potential must have a negative pregnancy test.\n12. Female patient who is of child-bearing potential is eligible to participate but must use an acceptable form of birth control method, including abstinence, hormonal contraception for at least 3 months in combination with a barrier method, intrauterine device (placement at least 3 months prior to screening), diaphragm with spermicide, cervical cap, condoms with contraceptive gel\u002Ffoam \u002Fcream, or surgical sterilization (tubal ligation at least 6 months prior to screening) or partner who had a vasectomy at least 6 months prior to screening\n13. Male patient with a female partner of child-bearing potential is eligible to participate but must be either documented to be surgically sterile (vasectomy), practicing complete abstinence for 90 days after study drug administration, or using two adequate forms of highly effective contraception (together with the female partner), one of which should be a physical barrier method, for 90 days after the study drug administration.\n\nExclusion Criteria:\n\n1. Subjects with primary malignancy of the central nervous system or malignancies related to human immunodeficiency virus (HIV) or solid organ transplant.\n2. Subjects who have not recovered from all toxic effects from prior antitumor therapy or surgical procedures, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 according to NCI CTCAE v5.0.\n3. Subjects with recent prior therapy defined as\n\n   1. Any investigational or Food and Drug Administration (FDA)-approved anti-cancer drug within 14 days or 5 half-lives, whichever is longer, prior to the first dose of study drug.\n   2. Any radiotherapy, chemotherapy, targeted therapy or immunotherapy within 14 days or major surgery within 28 days or anti-neoplastic antibody or nitrosoureas\u002Fmitomycin C within 42 days prior to the first dose of study drug\n4. Subjects with any uncontrollable diseases (e.g., severe mental, neurological, cardiovascular, respiratory, and other systemic diseases) or obvious active infections that may affect the clinical study.\n5. Subjects with positive Coronavirus disease（COVID）-19 PCR tests (patients who recovered from COVID-19 but have positive COVID-19 PCR tests may be included at the judgment of the Investigator)\n6. Subjects who have received the live or attenuated vaccine within 4 weeks prior to study treatment or intend to receive a live or attenuated vaccine during the study\n7. Presence of hepatitis B surface antigen (HBsAg) or positive hepatitis C antibody test result at screening or within 3 months prior to the first dose of study treatment. History of known HIV infection.\n\n   Note:\n   1. Subjects with positive Hepatitis C antibody due to prior resolved disease can be enrolled only if a confirmatory negative Hepatitis C RNA polymerase chain reaction (PCR) is obtained.\n   2. Subjects with well-controlled HIV may be enrolled if all the following criteria are met:\n\n      * must be stable on their anti-retroviral regimen, and participants must be healthy from an HIV perspective\n      * Participants must have a cluster of differentiation 4（CD4） count of greater than 250 cells\u002Fmicro litre（mcL ）over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count \\\u003C 200 cells\u002FmcL over the past 2 years unless it was deemed related to THE CANCER AND\u002FOR CHEMOTHERAPY-induced bone marrow suppression\n\n        \\- For patients who have received chemotherapy in the past 6 months, a CD4 count \\\u003C 250 cells\u002FmcL during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy\n      * Participants must have an undetectable viral load and a CD4 count \\>= 250 cells\u002FmcL within 7 days of enrollment\n      * Participants must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months. HIV-infected patients should be monitored every 12 weeks for viral load and CD4 counts\n8. Previous malignant disease (other than the target malignancy to be investigated in this trial) within the last 3 years. Subjects with a history of cervical carcinoma in situ, superficial or non-invasive bladder cancer or basal cell or squamous cell cancer in situ previously treated with curative intent may be included at the judgment of the Investigator.\n9. Subjects with symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. Note: Subjects previously treated for these conditions that have had stable central nervous system (CNS) disease (verified with consecutive imaging studies) for \\>1 month, are asymptomatic and off corticosteroids, or are on a stable dose of corticosteroids for at least 1 month prior to study Day 1 are permitted. The stability of brain metastases must be confirmed with imaging. The subject treated with gamma knife therapy can be enrolled 2 weeks post-procedure as long as there are no post procedure complications or the subject is stable.\n10. Subjects with active upper digestive tract ulcer or other disorders that can affect drug absorption, distribution, metabolism or clearance.\n11. Subjects with a marked baseline prolongation of QT\u002Fcorrected QT interval（QTc） interval (e.g., repeated demonstration of a QTc interval \\>480 milliseconds (CTCAE grade 1) using Fridericia QT correction formula.\n12. Subjects using concomitant medications known to prolong the QT\u002FQTc interval.\n13. Pregnancy or breastfeeding female; Female patients must be surgically sterile or be postmenopausal, or must agree to the use of effective contraception during the period of therapy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.\n14. Subjects who are unable to comply with study and follow-up procedures",{"count":102,"type":21},196,[53,104],"PHASE2","This is a Phase 1\u002F2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 administered orally as a single agent to patients with advanced solid tumors.\n\nThe study will include a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2a).\n\nEach part will consist of a screening period of up to 28 days, a treatment period, an end of treatment visit and a safety follow-up of approximately 30 days after the last dose. IPG7236 will be given on an empty stomach (either one hour before or two hours after a meal) twice daily (approximately every 12±1 hours) in continuous 28-day cycles.",[28,107,108],"Tolerability","Pharmacokinetics","2025-09-22",{"date":111,"type":33},"2025-09-24",{"date":113,"type":33},"2021-11-15",{"date":115,"type":21},"2025-12-21",{"name":117,"class":65},"Nanjing Immunophage Biotech Co., Ltd",7,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":137,"leadSponsor":139,"locationsCount":66},"100428626","the-safety-and-efficiency-of-endovascular-treatment-of-acute-or-subacute-thromboembolic-occlusions-of-lower-extremity-100428626","NCT04861506","The Safety and Efficiency of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.","Physician-initiated, Prospective, Multi-center, Observational Study: The Safety and Efficiency Result of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.","Inclusion criteria\n\n1. Patients aged 18 years or older.\n2. Diagnosis of acute or subacute limb ischemia classified as Rutherford classification stage I to IIb.\n3. Rutherford classification ranging from 3 to 5.\n4. Successful guidewire passage through the lesion of the femoropopliteal artery lesion, followed by further endovascular treatment. There are no restrictions will be implemented on the methods used for guidewire passage through the target lesion. The presence of thrombus must be confirmed via angiography and\u002For DSA and must be associated with occlusions of the lower extremity or ISR.\n5. Mechanical thrombectomy device (MTD) and\u002For pharmacomechanical thrombectomy (PMT) and\u002For percutaneous aspiration thrombectomy(PAT) and\u002For CDT (catheter-directed thrombolysis) performed for thrombus removal.\n6. The lower extremity artery must have a healthy runoff of at least 10 cm above the ankle with at least one healthy dorsalis pedis artery, medial plantar artery, or lateral plantar artery connecting to the digital artery below the ankle.\n7. Informed consent signed by patients.\n\nExclusion criteria\n\n1. Acute or subacute limb ischemia patients with Rutherford classification stage III.\n2. Patients diagnosed with thromboangiitis obliterans.\n3. Patients requring open surgery or hybrid operation after contrast radiography.\n4. Patients with a history of stroke, cerebral hemorrhage, gastrointestinal bleeding, myocardial infarction, or similar conditions in the past 3 months.\n5. Patients with known allergies to heparin, low molecular weight heparin, or contrast agents.\n6. Patients at high risk for bleeding.\n7. Pregnant or lactating women.\n8. Patients with other conditions that may complicate study participation or significantly reduce life expectancy (\\\u003C 2 years), such as tumors, severe liver disease, and cardiac insufficiency.\n9. Patients enrolled in other clinical studies within the past 3 months.\n10. Patients unwilling or refusing to sign the informed consent form.\n\n    \\-",{"count":20,"type":21},"OBSERVATIONAL","Based on the development of new tools, including drug coated balloon, paclitaxel eluting stent, interwoven stents, debulking tools, More and more acute or subacute thromboembolic occlusions of lower extremity included stage IIb were treated with endovascular procedures. Most guidelines suggests only stage I and stage IIa lesions are suitable for endovascular treatments. Therefore, a well-designed real-world study that track the safety and clinical relevant outcomes, are required to determine the optimal therapies for patients with acute or subacute thromboembolic occlusions of lower extremity.",[130,131,132,28,83],"Thromboembolic Disease","Lower Extremity Problem","Endovascular Treatment","2025-09-12",{"date":135,"type":33},"2025-09-15",{"date":88,"type":33},{"date":138,"type":21},"2025-12-31",{"name":140,"class":40},"First People's Hospital of Hangzhou",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":66},"100494930","phase-1-intracoronary-administration-of-omnimsc-ami-for-acute-st-segment-elevation-myocardial-infarction-patients-100494930","NCT05724576","Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients","Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention-Phase I Clinical Trial to Assess the Safety.","Inclusion Criteria:\n\n* Patents, with age ≤20 or ≤80 years old.\n* Fit to the definition of ST-elevation myocardial infarction (anterior myocardial infarction):\n\n  1. Chest pain onset.\n  2. 12-lead EKG:V1-V6 ≥ consecutive lead ST-segment elevation ≥1 mm.\n  3. TnT-I elevation.\n* Into emergency ≤ 6h upon AMI presentation.\n* Patients are willing to receive the treatment and sign the informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 20 or \\>80 years old.\n* History of\n\n  1. Malignancy.\n  2. Sepsis (abnormal WBC count elevation).\n  3. Hematologic disorder.\n  4. AIDS.\n  5. Advanced liver cirrhosis.\n  6. CKD stage 5 with Ccr \\\u003C15 ml\u002Fmin.\n* AMI occurrence \\> 6 hours\n* Non-first AMI.\n* Pregnancy or breastfeeding.\n* Prison.\n* Cancer treatment within 2 years.\n* Expected lifespan \\\u003C 6 months.\n* Non-suitable candidate evaluated by PI.\n* Participating in other clinical trials.","20 Years","80 Years",{"count":151,"type":21},10,[53],"This study will test the hypothesis intracoronary administration of OmniMSC-AMI (allogenic bone marrow-derived mesenchymal stem cells) just after finishing the primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients without cardiogenic shock is safe and may provide benefit on improving left ventricular ejection fraction (LVEF) during clinical follow-up.",[28],[156,157,158],"MSC","AMI","PCI","2025-06-04",{"date":161,"type":33},"2025-06-06",{"date":163,"type":33},"2023-06-26",{"date":165,"type":21},"2026-03-01",{"name":167,"class":65},"Taiwan Bio Therapeutics Inc.",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":66},"100581237","phase-1-single-ascending-dose-and-multiple-ascending-dose-study-of-avr-48-100581237","NCT06847698","Single Ascending Dose and Multiple Ascending Dose Study of AVR-48","Phase 1, Double-Blinded, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Safety and Pharmacokinetics Trial of AVR-48","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form (ICF).\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Healthy adult male or female, aged 18 to 55, inclusive, at Screening.\n4. Continuous non smoker who has not used nicotine containing products (including e- vaping) for at least 3 months prior to the first dosing and throughout the study\n5. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg\u002Fm2 at screening, and a minimum weight of at least 50.0 kg and a maximum weight of 100.0 kg at screening.\n6. Medically healthy with no clinically significant abnormalities in medical history, physical and neurologic examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.\n7. If female of childbearing potential, must be consistently using an effective method of contraception from screening visit until 30 days after the last drug administration.\n8. If female and not of childbearing potential, must be either surgically sterile or post menopausal (i.e., more than 1 year since last menstrual period).\n9. A non-vasectomized, male subject must agree to use an effective method of birth control with female partners of childbearing potential during the study and to refrain from donating sperm for 90 days following dosing.\n10. No restrictions are required for a vasectomized male subject provided his vasectomy has been performed 4 months or more (and have official documentation) prior to Study Day 1. A subject who has been vasectomized less than 4 months prior to Study Day 1 or does not have official documentation of his vasectomy must follow the same restrictions as a non-vasectomized subject.\n\nExclusion Criteria:\n\n1. Are mentally or legally incapacitated or have significant emotional problems at the time of the screening visit or expected during the conduct of the study in the opinion of the PI or designee.\n2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.\n3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.\n4. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.\n5. Has had surgery or any medical condition within 6 months prior to first dosing which may affect the distribution, metabolism, or elimination of the study drug, in the opinion of the PI or designee.\n6. Female subjects with a positive pregnancy test or who are lactating.\n7. Positive urine drug or alcohol results at screening or first check-in.\n8. Positive cotinine results at screening.\n9. Positive result at screening for tuberculosis (i.e., positive result for QuantiFERON TB-Gold).\n10. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).\n11. Unable to refrain from or anticipates the use of:\n\n    • Any drug, including prescription and non prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing and throughout the study. After first dosing, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the PI or designee. Hormone replacement therapy will be allowed.\n12. Donation or loss of 50 to 499 mL whole blood within 30 days or more than 499 mL whole blood within 56 days prior to the first dosing.\n13. Plasma donation within 14 days prior to the first dosing.\n14. Participation in another clinical study within 30 days prior to the first dosing. The 30 day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.\n15. Had a treatment with other investigational drug within 5 times the terminal elimination half-life (t1\u002F2), if known (e.g., a marketed product) or within 30 days (if the t1\u002F2 is unknown), whichever is longer, prior to Study Day 1 dosing.\n16. Evidence of Coronavirus Disease 2019 (COVID-19) infection.","55 Years",{"count":177,"type":21},48,[53],"This is a Phase 1 (healthy adult volunteers), 2-part, double-blind, randomized, placebo controlled trial to evaluate the safety and pharmacokinetic (PK) profiles of escalating single doses of AVR-48 versus placebo (SAD) and escalating multiple doses of AVR-48 versus placebo (MAD). SAD will be initiated first and include a sentinel dosing design. MAD will not utilize a sentinel design unless the safety monitoring committee requests the addition of sentinels. The MAD will be initiated once the lowest doses from SAD are deemed safe.",[28,107,108,181],"Pharmacodynamics","NOT_YET_RECRUITING","2025-04-03",{"date":185,"type":33},"2025-04-06",{"date":187,"type":21},"2025-06",{"date":189,"type":21},"2025-11",{"name":191,"class":65},"AyuVis Research, Inc.",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":4},"100585872","early-phase-1-safety-virological-and-immunological-assessment-of-the-controlled-dengue-human-infection-model-in-dengue-immune-participants-in-thailand-dhit-immune-100585872","NCT06908018","Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune)","DHIT-Immune","Inclusion Criteria:\n\n1. Thai healthy volunteers, aged between 18 to 40 years old, weight is greater than or equal to 50 kg and have Thai language literacy.\n2. Have not given blood donation in the past 3 months.\n3. Education: high school diploma or above\n4. Positive dengue-immune status against DENV-1 and\u002For DENV-3 and\u002For DENV-4 with naive DENV-2 status by the standard FRNT 50% (FRNT50) as follows: FRNT50 titer against\n\n   * DENV1 ≥ 1:5 and\u002For\n   * DENV3 ≥ 1:5 and\u002For\n   * DENV4 ≥ 1:5 with\n   * DENV2 ≤ 1:16\n5. Willingness to participate in the study as evidenced by signing the informed consent document.\n6. Female participants of childbearing potential should be agreed to either abstinence or use at least one primary form of contraception from the time of screening for rDEN2Δ30-7169 administration until 1 month after complete course of Dengue vaccination (Study Day 298).\n\nExclusion Criteria:\n\n1. For female participants: Currently pregnant, as determined by positive urine human choriogonadotropin (HCG) test or breast-feeding, and given birth or abortion within 6 months.\n2. History of previous acute undifferentiated febrile illness leading to hospitalization in the past 3 months.\n3. Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the subject's ability to understand and cooperate with the requirements of the study protocol.\n4. Any significant alcohol or drug abuse in the past 12 months that has caused medical, occupational, or family problems, as indicated by subject history.\n5. History of a severe allergic reaction or anaphylaxis.\n6. Severe asthma (emergency room visit or hospitalization within the last 6 months).\n7. Any known immunodeficiency syndrome.\n8. Having any pre-existing medical conditions consist of thrombocytopenia, autoimmune disease and cancer based on history, physical examination, and\u002For laboratory studies.\n9. Current use of anticoagulant medications (this includes anti-platelet medication such as aspirin or non-steroidal anti-inflammatory medications).\n10. Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 28 days prior to or following vaccination. An immunosuppressive dose of corticosteroids is defined as ≥ 10 mg of a prednisone equivalent per day for ≥ 14 days.\n11. Asplenia\n12. Receipt of any vaccine within 28 days or a killed vaccine within 14 days prior to receiving virus administration, or anticipated receipt of any vaccine during the 28 days following rDEN2Δ30-7169 administration.\n13. Has an obvious history of receiving any type of dengue vaccine or has previously participated in dengue vaccine research.\n14. Receipt of blood products within the past 6 months, including transfusions or immunoglobulin, or anticipated receipt of any blood products or immunoglobulin during the 28 days following rDEN2Δ30-7169 administration.\n15. History of allergy to Qdenga vaccine or any components of the vaccine.\n16. Previous episode of severe dengue infection defined by WHO 2009\n17. Screening laboratory values of Grade 1 or above (as defined in this protocol) for ANC (\\\u003C750 \u002Fmm3), Platelet (\\\u003C100,000 \u002Fmm3), PT (\\> 1.25 x ULN), APTT (\\> 1.66 x ULN), ALT (\\>2.5 x ULN) and plasma creatinine (\\> 1.3 x ULN OR Increase to \\>1.3 x participant's baseline).\n18. A participant with hemoglobin level less than 10 g\u002FdL at initial screening.\n19. Body temperature is greater than or equal to 38.0 °C (Oral)\n20. HIV infection, as indicated by anti-HIV screening assays.\n21. Hepatitis C virus (HCV) infection, as indicated by anti-HCV screening assays.\n22. Hepatitis B virus (HBV) infection, as indicated by hepatitis B surface antigen (HBsAg) and\u002For anti-HBc screening.\n23. Any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a subject participating in the trial, or would render the subject unable to comply with the protocol.","40 Years",{"count":201,"type":21},12,[203],"EARLY_PHASE1","rDEN2Δ30-7169 is a dengue challenge strain that previously reports its viremia induction effect in participants with minimal symptoms in US flavivirus naïve participants. Moreover, preliminary result of five Thai dengue naïve participants from previous project (registered number NCT05476757) demonstrated 100% viremia status without severe adverse event after 60 days post-virus challenge. However, result from previous project may not fully represent the clinical manifestation and immunological responses of major population of endemic areas, where most people in endemic area have dengue immune status. Therefore, this controlled human infection model protocol proposes to challenge the attenuated virus in 12 dengue-immune participants recruited from Bangkok metropolitan area, Thailand. We aim to assess the safety, viremia, NS1 antigenemia profile, and immunogenicity of the challenge virus in the dengue immune participants. After finish safety assessment, all participants will be vaccinated with a full course of dengue vaccines to prevent recurrent dengue infection. Immunological responses after vaccination will be also evaluated the vaccine efficacy.\n\nOur expected outcomes are all participants present viremia profiles after virus challenge without serious adverse events (SAE). The exploratory profiles include assesment of immune profiles and parameters comparison with the other dengue challenge study.",[28,206,207,208],"Dengue","Viremia","Immune-related Adverse Event","2025-04-01",{"date":183,"type":33},{"date":212,"type":21},"2025-09",{"date":214,"type":21},"2028-09",{"name":216,"class":40},"Mahidol University",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":66},"100530622","early-phase-1-phase-i-study-to-evaluate-kp405-in-healthy-and-parkinsons-disease-patients-100530622","NCT06189170","Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients","A Phase I, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate KP405. Part 1: Single Ascending Dosing in Healthy Participants. Part 2: Multiple Ascending Dosing in Healthy Participants and Parkinson's Disease Patients.","Inclusion Criteria:\n\n* Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examination, concomitant medication, vital signs, 12-lead ECG, cardiac Holter monitoring and clinical laboratory evaluations.\n* Clinical diagnosis of Parkinson's disease meeting United Kingdom Brain Bank criteria.\n\nExclusion Criteria:\n\n* Clinically relevant history of abnormal physical or mental health interfering with the study as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including \\[but not limited to\\], neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder), excluding Parkinson's disease.\n* Clinically significant, as judged by the Investigator, neurologic disorder (other than Parkinson's disease) including history of stroke or transient ischaemic attack within 12 months of Screening, cognitive impairment, seizure within 5 years of Screening or head trauma with loss of consciousness within 6 months of Screening.",{"count":225,"type":21},88,[203],"This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.",[28,229],"Tolerance","2025-03-04",{"date":232,"type":33},"2025-03-07",{"date":234,"type":33},"2024-08-01",{"date":236,"type":21},"2026-03-31",{"name":238,"class":65},"Kariya Pharmaceuticals",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":66},"100383294","early-de-escalation-of-empirical-antibiotics-treatment-for-neutropenic-fever-100383294","NCT04270786","Early De-escalation of Empirical Antibiotics Treatment for Neutropenic Fever","Phase III Randomized Study of Early De-escalation of Empirical Antibiotics Treatment for Neutropenic Fever in Patients Undergoing Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Age ≥18，patients undergo hematopoietic stem cells\n* Patients with neutropenic fever: T≥38.5°C once or T≥38°C twice a day with ANC \\\u003C0.5x109\u002FL or predicted to be \\\u003C0.5x109\u002FL in 24 \\~48 hours；\n* Patients achieved afebrile （T\\\u003C37.5°C）for at least 72 hours；\n* Inform consent given\n\nExclusion Criteria:\n\n* Patients with neutropenic fever with documented blood stream infection, skin and soft tissue infection, pneumonia and catheter associated infection.\n* Patients with septic shock\n* Levofloaxin allergy or contra-indication",{"count":247,"type":21},200,[24],"This is a randomized study to evaluate the safety and feasibility of early de-escalation of empirical antibiotics treatment in neutropenic fever patients undergoing hematopoietic stem cell transplantation (HSCT). In case of afebrile for 72 hours with empirical antibiotics treatment, patients will be randomized into 2 groups. In the early de-escalation group, antibiotics treatment will be stopped and prophylaxis with levofloxacin will be resumed. In the control group, the empirical treatment will continue until recovery of neutropenia or at least for 7 days.",[28],[252],"neutropenic fever, empiric, antibiotics","2025-02-14",{"date":255,"type":33},"2025-02-18",{"date":257,"type":33},"2020-01-01",{"date":259,"type":21},"2026-06-30",{"name":261,"class":40},"Shanghai Jiao Tong University School of Medicine",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":16,"sex":17,"minAge":148,"maxAge":269,"enrollmentInfo":270,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":285,"locationsCount":66},"100521970","pain-clinic-provides-public-health-safety-100521970","NCT06076512","Pain Clinic Provides Public Health Safety","Pain Clinic Provides Public Health and Safety Services","Inclusion Criteria:\n\n* adult chronic pain patients\n* patients with psychosocial problems\n\nExclusion Criteria:\n\n* pediatric patients\n* patients with severe cognitive dysfunction","99 Years",{"count":271,"type":21},1000,"Chronic pain is associated with psychological disorders; which may affect a patient's socioeconomic, legal, domestic, and employment situations. This prospective observational study evaluates the impact of pain management on patients' health, social, economic, and employment status. It explores the impact of pain clinic services on patients' mental health, family health, public health, road safety, addiction situation, public safety, injury rehabilitation and employment situation.",[274,275,28,276,277,278],"Social Functioning","Addiction, Substance","Road Injury","Patient Compliance","Chronic Pain","2025-01-23",{"date":281,"type":33},"2025-01-27",{"date":283,"type":33},"2018-02-02",{"date":138,"type":21},{"name":286,"class":40},"Salem Anaesthesia Pain Clinic",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":17,"minAge":148,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":66},"100484051","tenofovir-alafenamide-switch-therapy-in-chronic-hepatitis-b-100484051","NCT05583006","Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B","A Prospective Cohort Study of Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B Patients Who Are Unsatisfied to Entecavir Therapy","Inclusion Criteria:\n\n1. At least 20 years of age\n2. Detectable serum HBsAg\n3. Chronic HBV infection under ETV therapy\n4. ETV users who are unsatisfied with the efficacy and\u002For feel inconvenient of ETV therapy\n5. No contraindications for TAF switch therapy\n6. HBV antiviral period expectancy for at least 1 year\n\nExclusion Criteria:\n\n1. End stage renal disease (estimated glomerular filtration rate \\[eGRF\\]\\\u003C 15 mL\u002Fmin\u002F1.73m2) without dialysis\n2. Co-infected with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus\n3. Any active malignancies\n4. Under immunosuppressants\n5. Known allergy to tenofovir-contained regimens",{"count":295,"type":21},60,"Chronic hepatitis B (CHB) patients may be unsatisfied to entecavir (ETV) therapy due to the inconvenience in drug taking, i.e., fasting for more than 2 hours and\u002For dose adjustment according to estimated glomerular filtration rate (eGFR). However, tenofovir alafenamide (TAF) has been approved to be highly effective and safe in patients with CHB, and is convenient in drug taking, i.e., once daily regardless food taking and renal function.Therefore,TAF can be a good option in CHB patients who are unsatisfied to ETV therapy. The aim of this prospective cohort study is to assess the improvement on satisfaction (including drug adherence) of TAF switch therapy in CHB patients who are unsatisfied to ETV therapy. In addition, with expected adherence improvement in TAF switch therapy, the efficacy of TAF switch therapy may be improved, and the efficacy benefits can be evaluated by the changes of some novel biomarkers, such as HBV core-related antigen (HBcrAg). The investigators therefore aim to conduct a prospective cohort study of TAF switch therapy for CHB patients who are unsatisfied to ETV therapy.",[298,299,83,28],"Patient Satisfaction","Drug Adherence","2025-01-07",{"date":302,"type":33},"2025-01-09",{"date":304,"type":33},"2023-11-06",{"date":306,"type":21},"2028-12-30",{"name":308,"class":40},"Taichung Veterans General Hospital",{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":16,"sex":316,"minAge":18,"maxAge":75,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":318,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":327,"locationsCount":4},"100571635","phase-1-study-to-evaluate-lph-5-in-healthy-subjects-100571635","NCT06722820","Study to Evaluate LPH-5 in Healthy Subjects","Phase I, First-in-man, Randomised, Placebo-controlled, Single Dose Escalation Study to Investigate the Effects of LPH-5 on Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters in Healthy Participants","Inclusion Criteria:\n\n* Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examination, concomitant medication, vital signs, 12-lead ECG, and clinical laboratory evaluations.\n\nExclusion Criteria:\n\n* Any condition or disease detected during the medical interview\u002Fphysical examination that could relapse during or immediately after the study, or would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the clinical study, as determined by the Investigator.\n* Have a history of and\u002For current clinically significant determined by the Investigator\n* Consumes cannabis or cannabis-derived compounds more than 3 times per month or has substantial changes in cannabis consumption in the 21 days prior to screening.","MALE",{"count":177,"type":21},[53],"This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of LPH-5.",[28,229],"2024-12-03",{"date":323,"type":33},"2024-12-09",{"date":325,"type":21},"2025-04-30",{"date":138,"type":21},{"name":328,"class":65},"Lophora",{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":337,"targetDuration":339,"studyType":127,"phases":4,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":41},"100550751","lower-silesian-orbital-atherectomy-registry-loar-100550751","NCT06451146","Lower Silesian Orbital Atherectomy Registry (LOAR)","Evaluation of the Safety and Efficacy of Orbital Atherectomy (OA) for Calcified Lesions in Patients With Coronary Artery Disease: The Lower Silesian Orbital Atherectomy Registry (LOAR)","LOAR","Inclusion Criteria:\n\n* The presence of moderately to severely calcified lesions.\n\nExclusion Criteria:\n\n* Lack of patient consent\n* Target vessel perforation due to previous unsuccessful lesion preparation\n* Pregnancy",{"count":338,"type":21},500,"5 Years","The Lower Silesian Orbital Atherectomy Registry (LOAR), is an observational registry collecting all consecutive cases of percutaneous coronary intervention (PCI) performed with the support of the Orbital Atherectomy Device due to the presence of calcified lesion in coronary arteries. Data will be collected in two cooperating cardiac centers (Department of Cardiology, The Copper Health Center, Lubin, Poland, and Department of Cardiology, Provincial Specialized Hospital in Legnica, Poland).",[28,83],[343,344,345,346,347],"Percutaneous coronary interventions","Calcified Lesion","Coronary artery diseases","Orbital Atherectomy","Lesion preparation","2024-08-19",{"date":350,"type":33},"2024-08-21",{"date":352,"type":33},"2022-05-01",{"date":354,"type":21},"2027-05-01",{"name":356,"class":40},"Regional Cardiology Center, The Copper Health Centre (MCZ),",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":66},"100555238","nkg2d-car-tkd-025-in-the-treatment-of-advanced-nkg2dl-solid-tumors-100555238","NCT06509490","NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors","A Single-center, Open, Single-arm Clinical Study of the Safety and Efficacy of KD-025 CAR-T Therapy in Advanced NKG2DL+ Solid Tumors","Inclusion Criteria:\n\n1. Patients diagnosed as advanced solid tumors histopathologically or cytologically, such as ovarian, cholangiocarcinoma, and colorectal cancer.\n2. Patients fail standard treatment , or cannot tolerate standard treatment, or there is no standard treatment, the standard treatment recommendations refer to the latest version of the guidelines of the national comprehensive cancer network (NCCN) or the guidelines of the Chinese society of Clinical Oncology (CSCO);\n3. Age 18-70 years;\n4. ECOG score 0-1;\n5. Expected survival ≥ 3 months;\n6. Patients must meet coagulation parameters and have adequate peripheral venous access for apheresis, and must also have enough PBMC to manufacture CAR T cells;\n7. NKG2DL (according to the positive comprehensive score of 0-12 points, positive SCORE of NKG2DL ≥2) positive confirmed byImmunohistochemistry. Biopsy tissue must be no more than 1 year, if not, must obtain new tissue material from a recent surgical or diagnostic biopsy;\n8. Eligible organ and bone marrow functions defined as follows:1) Absolute neutrophil count ≥1.5×10\\^9\u002FL, lymphocyte count ≥0.5×10\\^9\u002F L, platelet count ≥90×10\\^9\u002FL, hemoglobin ≥90g\u002FL (no blood transfusion or Erythropoietin within 7 days); 2) Total bilirubin ≤2ULN; Serum alanine amino transferase (ALT) or aspartate aminotransferase (AST)≤2.5ULN (≤2.5 times with liver metastasis); 3) Creatinine ≤1.5ULN or eGFR≥ 60mL \u002Fmin\u002F1.73m\\^2 \\[eGFR=186×(age)-0.203×SCr-1.154(mg\u002Fdl), eGFR timing in women was 0.742\\]; 4) International normalized ratio (INR) or prothrombin time (PT) ≤1.5ULN; 5) Lung function: ≤ grade 1 dyspnea (according to NCI-CTCAE V5.0), SaO2≥91%; 6) Cardiac function: Cardiac ejection fraction (LVEF) detected by echocardiography or MUGA ≥50% 1 month before enrollment.\n9. Patients must have measurable lesions as defined by RECIST 1.1;\n10. Patients fully understand the test and voluntarily sign the informed consent;\n11. Patient agree to use approved contraceptive methods (e.g., birth control pills, barrier devices, iuds, contraindicated drugs) during the study and for at least 12 months after last cell infusion, until no CAR-T cells were detected by two consecutive PCR tests.\n\nExclusion Criteria:\n\n1. Patients had received any gene therapy (including CAR-T cell therapy) or any T cell therapy, Active bacteria or viral or fungal infection and not controlled after anti-infective treatment (positive blood test 72 hours before infusion), Syphilis, Human immunodeficiency virus (HIV), Active hepatitis B (HBV DNA≥500IU\u002Fml) or hepatitis c (anti-HCV positive and HCV RNA higher than the detection limit of analysis method);\n2. Patients have an autoimmune disease or organ transplant, require chronic systemic steroid therapy or any other form of immunosuppressive drugs;\n3. A history of serious heart or lung disease, including uncontrolled hypertension medication, and any condition that occurred within the past 6 months: congestive heart failure (New York Heart Association functional classification ≥3), cardiac angioplasty and stents, myocardial infarction, unstable angina, or other clinically severe heart disease;\n4. Detected clinically relevant central nervous system (CNS) metastases and\u002For pathologies, such as seizures, cerebral ischemia\u002Fbleeding, dementia, cerebellar diseases or autoimmune diseases affecting the CNS;\n5. The Patients' history or existing evidence of any condition such as neuroticism, psychosis, immunology, metabolism, and infectious disease, in any treatment, or laboratory abnormalities may confuse the outcome of the study, interfere with the Patients' participation during the study, or not participate in the Patients' best interests with investigator treatment;\n6. The Patients have a history of hematologic malignancy or concurrent history of other malignant primary solid tumors, except for: 1) Patients with cervical or breast cancer in situ who have no evidence of disease for more than 3 years after radical treatment; 2) Patients who have successfully received definite resection of tumor in situ and have no evidence of disease for ≥5 years;\n7. Received chemotherapy, radiation, small molecule, biologic cancer therapy, immunotherapy, or other experimental drugs within 4 weeks prior to study initiation,\n8. Pregnant or lactating women;\n9. The investigator considers the Patients have or with current historical evidence of any condition, therapy, or laboratory anomaly that may confound the results of the study, interfere with the Patients' participation in the fulltime study and the requirements of the cooperative trial, not controlled medical, psychological, family, social, or geographic conditions, or not participate.","70 Years",{"count":366,"type":21},9,[24],"This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of advanced NKG2DL+ solid tumors.",[28],"2024-07-14",{"date":372,"type":33},"2024-07-19",{"date":374,"type":21},"2024-07-17",{"date":376,"type":21},"2026-03-26",{"name":378,"class":40},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":388,"conditions":389,"keywords":395,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":416},"100554367","active-pharmacovigilance-study-of-the-medicine-rinvoq-upadacitinib-100554367","NCT06498167","Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)","LOOK-UP","Inclusion Criteria:\n\n* Prescription of Rinvoq™ from January 1, 2024;\n* 18 years of age or older at the time of recruitment; and\n* Expressed consent to participate in the study.\n\nExclusion Criteria:\n\n* They have any degree of cognitive impairment that prevents them from responding to a questionnaire administered by telephone;\n* They are participating in a phase I, II, or III clinical trial;\n* They have a life expectancy of less than 1 month; or\n* They do not have a valid telephone contact.",{"count":387,"type":21},150,"The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. The Marketing Authorisation Holder is AbbVie Deutschland GmbH \\& Co. KG.",[390,391,392,393,394,28],"Inflammatory Disease","Drug Side Effect","Drug Use","Adverse Drug Event","Adverse Drug Reaction",[396,397,398,399,400,401,402,403,404,405,406],"Upadacitinib","Rinvoq","Rheumatoid arthritis","Psoriatic arthritis","Axial spondyloarthritis","Atopic dermatitis","Ulcerative colitis","Crohn's disease","Pharmacovigilance risk","Drug safety monitoring","Patient Safety","2024-07-12",{"date":409,"type":33},"2024-07-15",{"date":411,"type":33},"2024-07-01",{"date":413,"type":21},"2024-12-31",{"name":415,"class":40},"Universidade do Porto",3,{"id":418,"slug":419,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":424,"enrollmentInfo":425,"targetDuration":4,"studyType":22,"phases":427,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":435,"leadSponsor":436,"locationsCount":66},"100553843","phase-2-first-line-treatment-induced-with-mfolfox6-and-hlx04-regimen-following-combined-with-serplulimab-in-mss-initially-unresectable-metastatic-colorectal-cancer-100553843","NCT06491355","First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer","Efficacy and Safety of First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer: A Prospective, Multicenter, Randomized, Controlled Trial (ASTRUM-IUmCRC)","Inclusion Criteria:\n\n1. The patient volunteered to participate in the study, signed the informed consent form, and had good compliance.\n2. Age: 18-75 years old (including 18 years old and 75 years old).\n3. Body weight of 40kg.\n4. Metastatic colorectal cancer confirmed by histology and \u002F or cytology and initially unresectable.\n5. MSS type or pMMR.\n6. Patients are required to have at least one measurable lesion (RECIST 1.1).\n7. ECOG physical strength status: 0-1 point.\n8. Expected survival of 12 weeks.\n9. Blood test (no transfusion within 14 days, no correction with granulocyte colony stimulating factor or other hematopoietic stimulating factor within 7 days before the laboratory test)\n\n   1. Absolute neutrophil value of 1.5109\u002F L, platelet 1010109\u002F L, hemoglobin concentration of 9 g\u002FdL);\n   2. Liver function test (bilirubin 1.5 ULN; aspartate aminase and glutamate aminase 2.5 ULN, AST and ALT 5 ULN);\n   3. Renal function (serum creatinine 1.5 ULN or creatinine clearance (CCr) 60 mL\u002Fmin);\n   4. Coagulation (international normalized ratio (INR) 1.5 ULN, prothrombin time (PT) and activated partial thromboplastin time (APTT) 1.5 ULN);\n   5. Thyroid function, upper limit of normal (TSH); if abnormal, FT3 and FT4 levels should be examined, normal FT3 and FT4 levels can be included.\n10. Women of childbearing age must have a negative serum pregnancy test within 14 days before treatment and be willing to use medically approved effective contraception (e. g., IU, contraceptives or condoms) during 3 months after the study and the last study drug; surgical sterilization for male subjects with a woman of childbearing age, or effective contraception is recommended during the study and 3 months after the last study dose.\n\nExclusion Criteria:\n\n1. Have received the following treatments within the first 4 weeks of treatment: tumor radiotherapy, surgery, chemotherapy, immune or molecular targeted therapy, and other clinical study drugs.\n2. Active autoimmune diseases requiring systemic treatment (i. e., corticosteroids or immunosuppressive agents) have occurred in the past 2 years. Alternative therapies (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are not considered systemic treatment.\n3. Diagnosis with immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first treatment. A physiological dose of corticosteroids may be approved after consultation with the investigator.\n4. Previous small molecule targeted drug therapy, such as fuquintinib, etc.\n5. Previous treatment with an oxaliplatin-based chemotherapy regimen.\n6. Symptomatic brain or meningeal metastases.\n7. Metastatic colorectal cancer with either MSI-H or dMMR.\n8. Severe infection (e. g. intravenous infusion of antibiotics, antifungals or antiviral drugs), or unexplained fever\\> 38.5℃ during screening \u002F first dose.\n9. Hypertension that is not well controlled with antihypertensive medication (systolic 140 mmHg or diastolic 90 mmHg).\n10. Significant clinical bleeding symptoms or significant bleeding tendency (bleeding\\> 30 mL, hematemesis, black feces, stool within 3 months), hemoptysis (\\> 5 mL of fresh blood within 4 weeks); or venous \u002F venous thrombosis events within 6 months, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; or long-term anticoagulation with Chinese standard or heparin, or long-term antiplatelet therapy (aspirin 300 mg \u002F day or clopidogrel 75 mg \u002F day).\n11. During screening, the tumor was found to invade large vascular structures, such as pulmonary artery, superior vena cava vein or inferior vena cava vein, which was judged to be at risk of large bleeding by the investigators.\n12. Active heart disease, including myocardial infarction, severe \u002F unstable angina, within 6 months before treatment. Echocardiography showed a left ventricular ejection fraction of \\\u003C50%, and the arrhythmia was poorly controlled.\n13. Other malignancies within or during the previous 5 years (except for cured skin basal cell carcinoma and carcinoma of the cervix in situ).\n14. Known allergy to the study drug or any of its excipients.\n15. Active or uncontrolled serious infection; A)known human immunodeficiency virus (HIV) infection; B) known history of clinically significant liver disease, including: viral hepatitis \\[known hepatitis B virus (HBV) carriers must exclude active HBV infection, namely HBV DNA positive (\\> 1104 copies \u002F mL or\\> 2000 IU \u002F mL); known hepatitis C virus infection (HCV) and HCV RNA positive (\\> 1103 copies \u002F mL)\\], or other hepatitis, cirrhosis;\n16. Any other disease, clinically significant metabolic abnormalities abnormal physical examination or laboratory abnormalities, according to the investigator, there is reason to suspect a disease or state is not suitable for the study drug (such as seizures and need treatment), or will affect the interpretation of the results, or make the patient in a high risk situation.\n17. Routine urine indicates urine protein 2 +, and 24-hour urine protein quantification\\> 1.0g.","75 Years",{"count":426,"type":21},72,[104],"This is a prospective, multi-center, randomized controlled clinical intervention study, aiming to explore the effectiveness and safety of mfolfox6 and hlx04 regimens combined with slulimumab as first-line treatment for MSS-type initial unresectable metastatic colorectal cancer after induction therapy. This study plans to include a total of 72 patients with untreated MSS-type initial unresectable metastatic colorectal cancer.\n\nThis study randomly allocated groups through a randomization system, and entered the following treatment groups at a ratio of 1:1: (1) Experimental group: mfolfox6 and hlx04 regimen induction therapy followed by slulimab treatment (36 cases); (2) Control group Group: mfolfox6 and hlx04 regimen treatment (36 cases).",[83,28,430],"Colo-rectal Cancer","2024-06-30",{"date":433,"type":33},"2024-07-09",{"date":411,"type":21},{"date":259,"type":21},{"name":437,"class":40},"Sir Run Run Shaw Hospital",{"id":439,"slug":440,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":16,"sex":17,"minAge":444,"maxAge":445,"enrollmentInfo":446,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":456,"leadSponsor":458,"locationsCount":4},"100550543","a-pilot-study-of-deep-cervical-lymphatic-venous-anastomosis-in-the-treatment-of-alzheimers-disease-100550543","NCT06448442","A Pilot Study of Deep Cervical Lymphatic-venous Anastomosis in the Treatment of Alzheimer's Disease","Inclusion Criteria:\n\n* a. aged 50-90 years (\\> or equal to 50 years old, \\\u003C or equal to 90 years old) were evaluated as Alzheimer's disease group according to the 2018 NIA-AA diagnostic criteria; B. signed by the patient or family informed consent; c. Patients with mild or moderate disease, 11≤MMSE≤26; d. Subjects with primary school education or above can complete the prescribed scale evaluation; The diagnosis of AD was confirmed by e.PET or cerebrospinal fluid examination\n\nExclusion Criteria:\n\n* a. any other disease that can cause cognitive impairment (e.g., dementia with Lewy bodies, frontotemporal dementia, Parkinson's disease dementia, etc.), intracranial mass impairing cognition, history of traumatic brain injury, normal pressure hydrocephalus, history of clinically significant cerebrovascular disease; b. Excluding other diseases affecting the nervous system, including nervous system infection, epilepsy, and systemic diseases affecting the function of the nervous system; c. Inability to cooperate with cognitive testing; d. Presence of contraindications to MRI examination (e.g., pacemakers, stents, claustrophobia, severe psychiatric symptoms, etc.).","50 Years","90 Years",{"count":447,"type":21},8,"Alzheimer's disease (AD) is the most prevalent form of dementia, affecting 3-4% of the population over a lifetime. It's characterized by abnormal Amyloid-beta (Aβ) and tau protein expression and accumulation in the central nervous system, leading to amyloid plaques and neurofibrillary tangles. While current treatments can slow cognitive decline, there's no cure.\n\nThe discovery of the \"glymphatic-meningeal lymphatic\" system has shed new light on cerebrospinal fluid circulation, showing it has a similar interstitial fluid system to peripheral lymphatic circulation. This system helps clear waste and transport nutrients in the brain, known as the glymphatic phenomenon. The deep cervical lymph nodes, part of this system, are crucial for cerebrospinal fluid drainage and are linked to the clearance of AD-related proteins.\n\nAging and inflammation can impair deep cervical lymph node function, increasing cerebrospinal fluid drainage pressure and potentially contributing to AD progression. Lymphatic anastomosis, a surgical technique used for lymphedema and other conditions, is being explored as a potential treatment to alleviate neurodegenerative disease by reducing cerebrospinal fluid pressure and clearing metabolic waste.",[28,450,451],"Feasibility","Therapeutic Value","2024-06-03",{"date":454,"type":33},"2024-06-07",{"date":234,"type":21},{"date":457,"type":21},"2028-08-01",{"name":459,"class":40},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":444,"enrollmentInfo":467,"targetDuration":4,"studyType":22,"phases":469,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":476,"leadSponsor":478,"locationsCount":66},"100550071","safety-and-tolerability-of-2-dietary-supplement-beverages-designed-to-maintain-healthy-blood-pressure-100550071","NCT06442293","Safety and Tolerability of 2 Dietary Supplement Beverages Designed to Maintain Healthy Blood Pressure.","An Evaluation of the Safety and Tolerability of 2 Dietary Supplement Beverages Designed to Maintain Normal Blood Pressure in Normal, Healthy Individuals.","Inclusion Criteria:\n\n* You are male or female between the ages of 18 and 50 (inclusive)\n* You are in generally good health and taking no medications known to treat or affect blood pressure (e.g., angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, diuretics)\n* You have a Body Mass Index of 18.5 to 30.0\n* You have a resting blood pressure of systolic blood pressure (SBP) of 90 - 120 mm Hg and a diastolic blood pressure (DBP) 60 - 80 mm Hg\n* You are comfortable reading and speaking in English\n* You are fully able and willing to comply with the requirements of the study\n* You are fully able and willing to keep scheduled appointments\n* You have no known food allergies or intolerances\n* Female individuals will be asked to complete a pregnancy screening test.\n\nExclusion Criteria:\n\n* You are pregnant, attempting to become pregnant, or are currently lactating\n* You currently use prescription or over-the-counter medications that may interfere with absorption of the test supplement or confound results (e.g., thiazide and loop diuretics for hypertension, corticosteroids)\n* You have clinically important gastrointestinal, renal, hepatic, cardiac, pulmonary, pancreatic, neurologic or biliary disorders or conditions. Individuals with type 1 or type 2 diabetes will be excluded from the study\n* You have illnesses or other medical conditions that will prevent or interfere with giving an informed consent, or with participation in the study.\n* You have scheduling difficulties or lack of transportation that will prevent or interfere with their ability to attend all the necessary study visits.\n* You have participated as a subject in any other clinical study within 30 days of the screening visit.\n* You have a history of alcohol abuse or other substance abuse within the previous 2 years.\n* You are currently using tobacco products including chewing tobacco and cigarettes.",{"count":468,"type":21},18,[24],"This study is designed to evaluate the safety and tolerability of two distinct dietary supplement beverage formulations designed to maintain normal blood pressure. In this study, safety and tolerability will be assessed among otherwise healthy, normotensive individuals.",[28,229],"2024-06-02",{"date":474,"type":33},"2024-06-04",{"date":411,"type":21},{"date":477,"type":21},"2024-08-15",{"name":479,"class":65},"USANA Health Sciences",{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":487,"targetDuration":4,"studyType":22,"phases":489,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":502},"100545551","evaluation-of-performance-safety-and-benefit-of-the-wishbone-ha-as-bone-graft-substitute-a-pre-market-clinical-investigation-100545551","NCT06383377","Evaluation of Performance, Safety and Benefit of the Wishbone HA as Bone Graft Substitute, a Pre-market Clinical Investigation","Prospective, Multi-center, Randomized, Single Blinded and Parallel Controlled Clinical Investigation to Assess the Performance, Safety and Benefit of the Wishbone HA Medical Device, a Deproteinized Bovine Bone Material, as a Bone Graft Substitute in the Socket Management Indication Requiring Bone Grafting Procedure Before Implant Placement.","Inclusion Criteria:\n\n* The subject signed the informed consent form;\n* The subject is ≥ 18 and ≤ 80 years old at surgery;\n* The subject is in need of a tooth extraction prior to implant placement;\n* All four bony walls are preserved after extraction;\n* Minimum 8mm height of bone;\n* Minimum 7mm thickness of lingual vestibular;\n* The subject is willing and able to comply with all investigation related procedures (such as exercising oral hygiene and attending all follow-up visits);\n* Full-mouth bleeding score (FMBS) lower than 25%;\n* Full-mouth plaque score (FMPI) lower than 25%.\n\nExclusion Criteria:\n\n* Subject with an acute infection (abscess) at the surgical site;\n* Subject with untreated periodontitis or periodontal disease;\n* Subject with autoimmune diseases or subjects that had received or were currently receiving treatment with antiresorptive drugs (e.g., bisphosphonates), or steroid therapy;\n* Subject who is pregnant or breastfeeding;\n* Subjects is a heavy smoker (\\>10 cigarettes a day);\n* Subject with an inability to conduct basic oral hygiene (poor oral hygiene and motivation);\n* Subject with metabolic diseases (diabetes, hyperparathyroidism, osteomalacia);\n* Subject with severe renal dysfunction and severe liver disease;\n* Subject with known severe osteoporosis;\n* Subject with multiple sclerosis and\u002For acromegaly;\n* Subject follows radiotherapy;\n* Subject with psychiatric disorders or under substance abuse (drug or alcohol);\n* Subject who participates in other clinical trials interfering with the present protocol;\n* Mucosal diseases in the areas to be treated.",{"count":488,"type":21},96,[24],"This investigation is a pre-market, prospective, multi-center, randomized, single blinded, parallel controlled clinical investigation performed in at least 5 clinical centers for confirmatory purposes of the use of WHA as intended in the filling of extraction sockets to enhance preservation of the alveolar socket.",[492,28],"Bone Regeneration","2024-05-28",{"date":495,"type":33},"2024-05-29",{"date":497,"type":33},"2024-04-26",{"date":499,"type":21},"2030-03-31",{"name":501,"class":65},"Wishbone SA",5,{"id":504,"slug":505,"hasResults":11,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":22,"phases":512,"briefSummary":513,"conditions":514,"keywords":517,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":528,"locationsCount":66},"100538222","comparison-of-total-tubeless-mini-pcnl-versus-tubeless-mini-pcnl-100538222","NCT06288022","Comparison of Total Tubeless Mini-PCNL Versus Tubeless Mini-PCNL","Comparison of Total Tubeless Mini-PCNL Versus Tubeless Mini-PCNL : A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients diagnosed with kidney stones with a size ranging from 20 to 40 millimeters.\n* Patients have undergone mini-PCNL, unilateral\n* Absence of urinary tract infections before surgery.\n* No urological congenital abnormality\n* No coagulopathy\n\nExclusion Criteria:\n\n* Presence of residual stones after the surgery, fragments larger than 4 millimeters.\n* Patients with a single functioning kidney\n* Complicated cases, including:\n\n  1. massive bleeding in the upper tract during surgery\n  2. Severe collecting systems injury during surgery\n  3. Severe UPJ mucosa swelling considered unsafe by the physician, requiring the placement of a DJ stent or nephostomy tube\n* Participants who decline or request withdrawal from the research study.",{"count":511,"type":21},130,[24],"Limited literature has focused on the use of totally tubeless mini-percutaneous nephrolithotomy (Mini-PCNL) for the treatment of large renal stones.\n\nThis Randomized Controlled trial aims to compare complication and safety of Mini-PCNL between total tubeless and tubeless Mini-PCNL.",[515,516,28],"Surgery-Complications","Nephrolithiasis Staghorn Calculus",[518,519,520,521],"total tubeless PCNL","complication","safety","tubeless PCNL","2024-03-05",{"date":524,"type":33},"2024-03-07",{"date":526,"type":21},"2024-04-01",{"date":259,"type":21},{"name":216,"class":40},{"id":530,"slug":531,"hasResults":11,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":538,"conditions":539,"keywords":540,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":41},"100537917","lower-silesia-culotte-bifurcation-registry-lscbr-100537917","NCT06284057","Lower Silesia Culotte Bifurcation Registry (LSCBR).","Double Kissing (DK) vs Culotte Culotte. Lower Silesia Culotte Bifurcation Registry (LSCBR).","LSCBR","Inclusion Criteria:\n\n* Presence of significant changes in the coronary bifurcation requiring the implantation of two coronary stents using the Culotte or DK Culotte technique.\n\nExclusion Criteria:\n\n* Patients who underwent PCI with coronary stents prior to the index procedure for the bifurcation lesion studied.",{"count":20,"type":21},"The study aimed to evaluate the outcomes of bifurcation PCI using two techniques (Culotte vs. DK-Culotte) using data from a retrospective analysis.",[28,83],[541,542,543,544,545,546],"Percutaneous coronary intervention (PCI)","Bifurcation lesion","Culotte Technique","Double Kiss Culotte Technique","Acute Coronary Syndrome","Two-Stent Technique","2024-03-03",{"date":549,"type":33},"2024-03-06",{"date":551,"type":33},"2013-04-01",{"date":553,"type":21},"2028-04-01",{"name":356,"class":40},{"id":556,"slug":557,"hasResults":11,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":563,"targetDuration":339,"studyType":127,"phases":4,"briefSummary":564,"conditions":565,"keywords":566,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":41},"100538233","lower-silesia-sinus-reducer-registry-100538233","NCT06288165","Lower Silesia Sinus Reducer Registry","Coronary Sinus Reducer Implantation for Refractory Angina - Long-Term Evaluation of Device Safety and Efficacy- Lower Silesia Sinus Reducer Registry (LSSRR)","LSSRR","Inclusion Criteria:\n\n1. present of chronic disabling refractory angina pectoris (Canadian Cardiovascular Society \\[CCS\\] classes 2-4) despite maximally tolerated anti-angina medical therapy\n2. Heart team evaluation with consideration of ineligibility for percutaneous or surgical revascularization procedures.\n\nExclusion Criteria:\n\n1. recent acute coronary syndrome (\\\u003C3 months),\n2. recent coronary revascularization (\\\u003C3 months)\n3. a mean right atrial pressure higher than 15 mm Hg\n4. coronary sinus proximal diameter \\\u003C10mm and \\>14mm\n5. life expectancy under 12 months,\n6. advanced heart failure (New York Heart Association \\[NYHA\\] Classification - classes 3-4),\n7. potential implantable cardiac resynchronization therapy defibrillator (CRT-D) implantation candidate.",{"count":247,"type":21},"Lower Silesia Sinus Reducer Registry is a , single-center, single-arm registry including patients with chronic disabling refractory angina pectoris (Canadian Cardiovascular Society \\[CCS\\] classes 2-4) despite maximally tolerated anti-angina medical therapy who underwent Coronary Sinus Reducer implantation .",[28,83],[567,568,569,570,571],"Coronary Sinus Reducer","Refractory angina","Chronic coronary artery diseases (CAD)","Non-obstructive Coronary artery diseases (CAD)","Coronary microvascular dysfunction","2024-02-24",{"date":574,"type":33},"2024-03-01",{"date":576,"type":33},"2022-05-11",{"date":578,"type":21},"2027-05-11",{"name":356,"class":40},{"id":581,"slug":582,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":269,"enrollmentInfo":588,"targetDuration":339,"studyType":127,"phases":4,"briefSummary":589,"conditions":590,"keywords":591,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":600,"leadSponsor":601,"locationsCount":41},"100509704","the-lower-silesia-shockwave-registry-100509704","NCT05916898","The Lower Silesia Shockwave Registry","Evaluation of the Safety and Efficiency of ShockWave Intravascular Lithotripsy (S-IVL) in Coronary Artery Diseases. The Lower Silesia Shockwave Registry (LSSR)","LSSR","Inclusion Criteria:\n\n* The presence of moderately to severely calcified lesions.\n* The presence of significant under-expansion (greater than 20% of the diameter) of the previously implanted stent.\n* Initial failure of the lesion preparation with either the NC balloon catheter or the atherectomy device.\n\nExclusion Criteria:\n\n* Lack of patient consent\n* Target vessel dissection type 3 or higher according to spontaneous coronary artery dissection (SCAD) classification\n* Target vessel perforation due to previous unsuccessful lesion preparation\n* Pregnancy",{"count":20,"type":21},"Lower Silesia Shockwave Registry (LSSR), is a observational registry collecting all consecutive cases of percutaneous coronary intervention (PCI) performed with the support of shockwave intravascular lithotripsy in two cooperating cardiac centers (Department of Cardiology, The Copper Health Centre, Lubin Poland, and Department of Cardiology, Provincial Specialized Hospital in Legnica, Poland).",[28,83],[343,344,592,593,345,594,595],"Shockwave intravascular lithotripsy","Stent under-expansion","lesion preparation","stent optimalization","2023-06-21",{"date":598,"type":33},"2023-06-23",{"date":352,"type":33},{"date":354,"type":21},{"name":356,"class":40},{"id":603,"slug":604,"hasResults":11,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":609,"enrollmentInfo":610,"targetDuration":4,"studyType":22,"phases":611,"briefSummary":612,"conditions":613,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":66},"100479000","dcb-versus-primary-selective-stenting-in-tasc-cd-femoropopliteal-artery-disease-100479000","NCT05517291","DCB Versus Primary Selective Stenting in TASC C\u002FD Femoropopliteal Artery Disease","Paclitaxel Coated Balloon Angioplasty Versus Primary Selective Stenting in the Treatment of TASC C\u002FD Chronic Femoropopliteal Artery Occlusive Disease: A Multicenter Randomized Clinical Trial","Inclusion Criteria:\n\n* Subject age 18-85yrs.\n* Subject has been informed of the nature of the study, agrees to participate, and has signed a Medical Ethics Committee approved consent form.\n* Subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing.\n* Rutherford category 2-5.\n* Subject has a de novo TASC C\u002FD femoropopliteal artery lesions which does not exceed to the segment P1 of popliteal artery.\n* The total length of target lesion ≤30cm.\n* Reference vessel diameter \\>4 mm and \\\u003C6.5 mm by visual assessment.\n* Patent inflow artery with stenosis \\\u003C30% and at least 1 infrapopliteal artery to the ankle (\\\u003C50% diameter stenosis).\n* A guidewire has successfully traversed the target treatment segment.\n\nExclusion Criteria:\n\n* Acute thrombus in the target vessels.\n* Vessel stenosis or occlusion due to Buerger's disease or autoimmune arteritis.\n* Subject received prior stents implantation with in-stent restenosis or occlusion.\n* Reintervention of the target lesion \\\u003C90 days before the study procedure.\n* Acquired thrombophilia or uncontrolled hypercoagulation states.\n* Life expectancy \\\u003C12 months.\n* Severe renal（SCr≥2.5 mg\u002Fdl）or hemodialysis dependence.\n* Pregnancy, suspected pregnancy, or breastfeeding during study period.\n* Contraindication to contrast media or any study-required medication (antiplatelet, anticoagulant, or thrombolytic agents, etc.).\n* Hypersensitivity to nitinol and\u002For paclitaxel.","85 Years",{"count":247,"type":21},[24],"This study aims to compare the mid- and long-term outcomes between paclitaxel-coated balloon and primary selective stenting in the treatment of TASC C\u002FD femoropopliteal artery occlusive disease.",[28,83],"2022-12-04",{"date":616,"type":33},"2022-12-06",{"date":618,"type":33},"2022-09-18",{"date":620,"type":21},"2027-12-31",{"name":622,"class":40},"Peking Union Medical College Hospital"]